Background: HIV assays designed to detect recent infection, also known as “recency
assays,” are often used to estimate HIV incidence in a specific country, region, or …

Standard‐of‐care HIV pre‐exposure prophylaxis (PrEP) is highly efficacious, but uptake of
and persistence on a daily oral pill is low in many settings. Evaluation of alternate PrEP …

Background Antiretroviral therapy (ART) cannot cure HIV infection because of a persistent
reservoir of latently infected cells. Approaches that force HIV transcription from these cells …

Background It is frequently of epidemiological and/or clinical interest to estimate the date of
HIV infection or time-since-infection of individuals. Yet, for over 15 years, the only widely …

Antiretroviral therapy (ART) during acute HIV infection (AHI) interrupts viral dynamics and
may delay the emergence of serological markers targeted by current HIV screening and …

Background Two manufacturers, Maxim Biomedical and Sedia Biosciences Corporation,
supply CDC-approved versions of the HIV-1 Limiting Antigen Avidity EIA (LAg) for detecting …

Human immunodeficiency virus types 1 and 2 (HIV-1 and HIV-2) diagnostic testing
algorithms recommended by the Centers for Disease Control involve up to three tests and …

Background Given the challenges and costs associated with implementing HIV-1 incidence
assay testing, there is great interest in evaluating the use of commercial HIV diagnostic tests …

Background: We investigated whether deep sequencing of archived HIV DNA of
antiretroviral-naive persons with acute/early HIV infection could identify transmitted drug …

Background Early detection of acute HIV infection by HIV antigen/antibody assays depends
on antigen sensitivity. Maintaining consistently high sensitivity across diverse HIV strains is …